"Drug Resistance, Fungal" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The ability of fungi to resist or to become tolerant to chemotherapeutic agents, antifungal agents, or antibiotics. This resistance may be acquired through gene mutation.
| Descriptor ID |
D025141
|
| MeSH Number(s) |
G06.225.383 G07.690.773.984.269.383
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Fungal".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Fungal".
This graph shows the total number of publications written about "Drug Resistance, Fungal" by people in this website by year, and whether "Drug Resistance, Fungal" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Fungal" by people in Profiles.
-
Leidner F, Kurt Yilmaz N, Schiffer CA. Deciphering Antifungal Drug Resistance in Pneumocystis jirovecii DHFR with Molecular Dynamics and Machine Learning. J Chem Inf Model. 2021 06 28; 61(6):2537-2541.
-
Hoenigl M, Levitz SM, Schuetz AN, Zhang SX, Cornely OA. All You Need to Know and More about the Diagnosis and Management of Rare Mold Infections. mBio. 2021 02 23; 12(1).
-
Agudelo CA, Mu?oz C, Ram?rez A, Tob?n AM, de Bedout Bact C, Cano LE, Restrepo A. Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole. Rev Iberoam Micol. 2015 Oct-Dec; 32(4):214-20.
-
Yoon C, Subramanian A, Chi A, Crothers K, Meshnick SR, Taylor SM, Beard CB, Jarlsberg LG, Lawrence GG, Avery M, Swartzman A, Fong S, Roth B, Huang L. Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort. Med Mycol. 2013 Aug; 51(6):568-75.
-
Kourkoumpetis TK, Fuchs BB, Coleman JJ, Desalermos A, Mylonakis E. Polymerase chain reaction-based assays for the diagnosis of invasive fungal infections. Clin Infect Dis. 2012 May; 54(9):1322-31.
-
Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials. 2007 Mar-Apr; 8(2):86-97.
-
Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D, Hare R, Boparai N, Isaacs R. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin Infect Dis. 2007 Feb 15; 44(4):607-14.
-
Huang L, Welsh DA, Miller RF, Beard CB, Lawrence GG, Fox M, Swartzman A, Bensley MR, Carbonnet D, Davis JL, Chi A, Yoo BJ, Jones JL. Pneumocystis jirovecii dihydropteroate synthase gene mutations and human immunodeficiency virus-associated Pneumocystis pneumonia. J Eukaryot Microbiol. 2006; 53 Suppl 1:S114-6.
-
Wheat LJ, Connolly P, Smedema M, Brizendine E, Hafner R. Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clin Infect Dis. 2001 Dec 01; 33(11):1910-3.